Effects of N-acetylcysteine TGF-β1 and IL-13 on idiopathic pulmonary fibrosis
LI Ming-sheng
LU Ming-you
ZHENG Xiao-lu
LI Ji-fu
SHI Li-ya
CHEN Yong-de
Abstract：Objective To investigate the significance of expression of transforming growth factor β1 (TGF-β1)and interleukin 13 in patients with idiopathic pulmonary fibrosis(IPF) though Fluimucil. Methods One hun-dred and twenty-two IPF patients were randomly divided into two groups. Treatment group included 62 cases treated with prednisone 0.5 mg/kg per day orally and the dosage was reduced 50% 4 weeks later and Fluimucil 600 mg three times per day. Control group included 60 cases receiving prednisone 0.5 mg/kg per day orally and a half dos-age 4 weeks later. The clinical manifestation, pulmonary function testing, high-resolution chest CT, arterial blood gas analysis were observed before and 3 months after treatment. Results After treatment of 3 months, the improve-ment rate of symptoms and signs in the treatment group was superior to that in the control group (P < 0.05 ). The se-rum levels of TGF-β1 and IL-13 in the treatment group were decreased significantly(P < 0.05 ). Conclusion Flu-imucil can improve symptoms and signs of the patient with pulmonary interstitial fibrosis via decreasing TGF-β1 and IL-13.
Keywords：Idiopathic pulmonary fibrosisN-acetylcysteineTransforming growth factor β1Interleu-kin 13
Publication Date：2009-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 691-693 )